PR91394

MONTREAL, Aug. 31, 2021 /PRNewswire=KYODO JBN/ --

CellCarta and Olink Proteomics AB announced today a strategic collaboration to

offer Olink(R) Target 96 & Target 48 to pharmaceutical and biotech customers,

advancing targeted protein biomarker quantification in clinical studies.

Logo -

https://mma.prnewswire.com/media/1604786/CellCarta_CellCarta_expands_its_biomarker_capabilities_for_clini.jpg

CellCarta is a global leader in precision medicine and with more than 20 years

of experience in mass spectrometry the company continues to invest in the field

of proteomic biomarkers to better understand diseases and support therapeutic

development projects. With the acquisition of the first Olink(R) Signature Q100

instruments and the collaborative support of Olink, CellCarta becomes the first

global clinical CRO to offer the technology. "Complementing our mass

spectrometry platforms with the Proximity Extension Assay (PEA) technology from

Olink will allow us to support our clients with comprehensive proteomic

services for their clinical studies. As the translational medicine community is

turning to multi-omic analysis to address challenging questions in therapeutic

development, we see Olink coupling with our other platforms (immune monitoring,

histopathology, genomics) to create additional value for our clients," said

Nick Wright, President and Global COO of CellCarta.

The Olink platform offers an unmatched high-multiplex technique to quantify

protein biomarkers using minimal clinical sample volume, with exceptional

sensitivity and specificity, while covering a broad dynamic range. Differing

from other multiplex protein detection platforms, Olink's PEA technology

provides high specificity by avoiding cross-reactivity binding or interference

at signal readout with its dual recognition approach with matched pairs of

antibodies labeled with complementary DNA oligos.  

Olink fills the need for a robust technology that elevates clinical proteomics

and is a must in a field driven by low abundant biomarkers, such as

immuno-oncology.

Through this collaboration, CellCarta will bring the Q100 platform into its

CAP/CLIA laboratories to address the need for proteomic biomarkers for clinical

trials and support multi-omics analysis with its CellEngine(TM) software (https://c212.net/c/link/?t=0&l=en&o=3274690-1&h=3418189780&u=https%3A%2F%2Fcellcarta.com%2Fcellenginesoftware%2F&a=CellEngine%E2%84%A2+software). CellCarta's global footprint, with sites in the US, Canada, Belgium,

Australia, and China, will allow for rapid deployment of the platform and

support clients in their global clinical programs.

"We are excited to enter this strategic collaboration with CellCarta to broaden

the access to our protein biomarker solutions. CellCarta is well positioned in

the pharma services market as a leading specialty CRO and is a logical choice

for this collaboration to elevate the analysis of proteomic biomarkers in

clinical trials specimens. Enabling proteomic analysis along with other key

technologies in clinical biomarker programs will increase their value and

achieve insights which only true multi-omic analyses can provide," said Jon

Heimer, CEO of Olink Proteomics.

About Olink

Olink Holding AB (publ) (Nasdaq: OLK) is a company dedicated to accelerating

proteomics together with the scientific community, across multiple disease

areas to enable new discoveries and improve the lives of patients. Olink

provides a platform of products and services which are deployed across major

biopharmaceutical companies and leading clinical and academic institutions to

deepen the understanding of real-time human biology and drive 21st century

healthcare through actionable and impactful science. The company was founded in

2016 and is well established across Europe, North America and Asia. Olink is

headquartered in Uppsala, Sweden. For more information, please visit

www.olink.com

About CellCarta

CellCarta is a leading provider of specialized precision medicine laboratory

services to the biopharmaceutical industry. Leveraging its integrated

analytical platforms in immunology, histopathology, proteomics and genomics, as

well as related specimen collection and logistics services, CellCarta supports

the entire drug development cycle, from discovery to late-stage clinical

trials. The company operates globally with 10 facilities located in Canada,

USA, Belgium, Australia, and China. For more information:  

www.cellcarta.com            

Media contacts: CellCarta, Guylaine Galipeau, Global Marketing Director,

ggalipeau@caprion.com; Olink, Carl Raimond, Chief Commercial Officer,

carl.raimond@olink.com

SOURCE CellCarta